Mantle Cell Lymphoma | Tumor

Bendamustine-Rituxan Combination Shows Promise in Frontline Treatment of Most Patients with Mantle Cell Lymphoma

September 2nd 2020, 1:00pm


“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an effective, safe, and ideally outpatient regimen for MCL,” the authors wrote.

The Latest News and Updates in Mantle Cell Lymphoma

August 11th 2020, 1:00pm


A roundup of the latest news and updates for patients with mantle cell lymphoma from CURE®.

Options for Patients with Mantle Cell Lymphoma Are 'Exploding', Expert Says

August 10th 2020, 7:00pm


“It really is an exciting time for patients with lymphoma, because the options are just really exploding at a very encouraging rate,” said Dr. Lori A. Leslie.

Approval of First CAR T-Cell Therapy for Relapsed/Refractory MCL to Change How Patients are Treated 'Forever and for the Better'

August 4th 2020, 10:00pm


“The FDA approval of (Tecartus) will change the way we treat patients with relapsed MCL forever and for the better,” said Dr. Michael Wang.

5 Recent FDA Approvals Patients with Cancer May Have Missed

August 3rd 2020, 7:00pm


The Food and Drug Administration has had a busy summer, approving new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

No 'One Great Answer' When it Comes to What Rights Those Affected By Cancer Have When Returning to Work Amid COVID-19

July 29th 2020, 7:00pm


There are some job protected options for patients with cancer, survivors and caregivers to consider when it comes to returning to work during the COVID-19 pandemic. But, as one cancer rights attorney notes, there are many challenges to those options.

FDA Approves First CAR T-Cell Therapy, Tecartus, for Relapsed or Refractory Mantle Cell Lymphoma

July 24th 2020, 10:44pm


The FDA’s approval of Tecartus for adults with relapsed or refractory mantle cell lymphoma (MCL) is based on data that showed that the CAR T-cell therapy induced a response in 87% of patients.

Several Leading Cancer Organizations Urge US to Reconsider Withdrawing from the World Health Organization

July 22nd 2020, 1:50am


Patients with cancer have been encouraged to reach out to legislators and share their personal stories and advocate for why they think continued funding is important to further cancer research.

Expert Advises Genetic Profiling in MCL Can Be a Useful Tool in Treating The Disease

July 7th 2020, 10:57pm


“We learned from previous prospective studies (that) using chemoimmunotherapy for those patients with TP53 aberrations, the survival data compared with others that do not harbor this mutation are much less favorable,” said Dr. Jia Ruan.

Analysis Identifies Predictors of Survival in Older Patients With Mantle Cell Lymphoma

July 7th 2020, 5:58pm


“It is important to note that the data predates the widespread use of BTK inhibitors and even cellular therapies such as CAR T-cell therapy, specifically,” Dr. Reem Karmali said in an interview. “And so, it doesn't reliably reflect the potential advancements and survival that we've been able to achieve with these novel targeted therapies.”